enzymelink
immunosorb
assay
elisa
use
determin
level
specif
igg
antibodi
measl
rubella
vaccinia
corona
mump
virus
cerebrospin
fluid
csf
serum
patient
clinic
definit
multipl
sclerosi
ms
patient
optic
neuriti
patient
neurolog
diseas
ond
control
subject
without
central
nervou
system
diseas
serum
antibodi
level
significantli
differ
four
group
differ
frequenc
level
csf
antibodi
four
group
observ
control
patient
serumcsf
antibodi
ratio
log
averag
correspond
differ
serum
csf
antibodi
level
ms
patient
ratio
averag
averag
patient
averag
ond
patient
similar
control
alter
serumcsf
ratio
sever
virus
within
individu
patient
similar
result
suggest
nonspecif
immunostimul
respons
increas
level
csf
viru
antibodi
introduct
increas
antibodi
titer
sever
virus
lbund
cerebrospin
fluid
csf
multipl
sclerosi
ms
patient
constant
find
elev
level
measl
antibodi
elev
rubella
herp
simplex
vaccinia
mump
antibodi
also
found
hair
norrbi
rel
amount
csf
antibodi
compar
serum
antibodi
level
higher
mani
ms
patient
control
associ
intrathec
synthesi
antibodi
frick
sheidseydel
tourtellott
parker
norrbi
howev
low
sensit
convent
serolog
techniqu
limit
evalu
csf
antibodi
level
normal
control
due
low
amount
antivir
antibodi
present
recent
develop
sensit
enzym
immunoassay
viru
antibodi
leinikki
pissili
leinikki
et
al
use
techniqu
studi
occurr
level
csf
antibodi
unrel
viral
antigen
ms
control
group
patient
admit
outpati
depart
neurolog
univers
central
hospit
helsinki
finland
lumbar
punctur
perform
admiss
initi
includ
care
clinic
laboratori
investig
subsequ
establish
diagnosi
place
patient
either
clinic
definit
ms
optic
neuriti
neurolog
diseas
ond
control
group
criteria
ms
schumach
et
al
exclus
neurolog
diseas
control
group
base
cfinic
examin
follow
admiss
clinic
followup
altogeth
ms
patient
ond
patient
studi
control
group
includ
subject
symptom
headach
vertigo
pain
neck
hyperventil
without
evid
central
nervou
system
cn
diseas
csf
code
studi
laboratori
elisa
viral
antibodi
dispos
polystyren
cuvett
photomet
labsystem
hetsinki
finland
use
describ
earlier
leinikki
pissili
measl
edmonston
strain
rubella
gilcrest
strain
antigen
leinikki
et
al
prepar
purifi
virion
sucros
gradient
crude
commerci
avail
vaccinia
microbiolog
associ
bethesda
md
mump
ender
strain
use
leinikki
et
al
coronaviru
antigen
prepar
grow
strain
mous
brain
purifi
sucros
gradient
heavi
chainspecif
alkalin
phosphataseconjug
antihuman
igg
prepar
describ
earlier
leinikki
pissili
serum
sampl
dilut
csf
dilut
amount
antibodi
calcul
logarithm
scale
dilut
sampl
compar
dilut
fig
distribut
mean
serumcsf
viru
measl
rubella
vaccinia
corona
mump
antibodi
ratio
log
relat
bloodbrain
barrier
function
differ
patient
group
note
ratio
highest
control
subject
lowest
ms
patient
without
relat
bloodbrain
barrier
intact
bloodbrain
barrier
moder
impair
bloodbrain
barrier
sever
impair
bloodbrain
barrier
associ
impair
bloodbrain
barrier
casein
ms
patient
fig
averag
serumcsf
ratio
differ
viral
antibodi
studi
group
present
tabl
control
group
show
rel
littl
variat
one
viru
antibodi
anoth
averag
antibodi
correspond
differ
serum
csf
antibodi
msthe
averag
ratio
vari
vaccinia
mump
viru
antibodi
overal
averag
ratio
ms
patient
control
vaccinia
viru
antibodi
ratio
less
deriv
two
patient
averag
ratio
ond
patient
slightli
lower
control
serumcsf
ratio
analyz
statist
multipl
regress
analysi
compar
data
serum
csf
protein
includ
csf
total
protein
csf
albumin
serumcsf
albumin
ratio
signific
correl
found
ms
group
indic
alter
serumcsf
antibodi
ratio
due
alter
bloodbrain
barrier
serumcsf
antibodi
ratio
gener
similar
differ
virus
individu
patient
equal
true
control
patient
normal
ratio
well
ms
patient
abnorm
ratio
exampl
given
tabl
sensit
test
permit
detect
csf
antibodi
amount
low
detect
convent
serolog
method
serumcsf
ratio
total
igg
log
scale
normal
healthi
individu
alter
ratio
may
associ
situ
format
antibodi
cn
impair
bloodbrain
barrier
increas
sensit
present
elisa
techniqu
made
possibl
detect
viral
antibodi
csf
major
control
subject
fact
individu
serum
antibodi
measl
andor
rubella
detect
level
csf
corona
vaccinia
mump
viru
antibodi
occur
low
concentr
serum
could
detect
csf
simultan
elev
multipl
antibodi
level
csf
ms
patient
clearli
demonstr
present
studi
role
evolut
viral
antibodi
csf
ms
patient
understood
divers
viral
agent
implic
ms
make
improb
agent
crossreact
unknown
agent
would
caus
simultan
multipl
antibodi
stimulu
observ
studi
best
explan
viral
antibodi
produc
within
cn
ms
patient
relat
immunopathophysiolog
diseas
rather
specif
etiolog
alter
serumcsf
viru
antibodi
ratio
also
occasion
detect
among
patient
neurolog
diseas
norrbi
iivanainen
et
al
diseas
subacut
scleros
panenceph
sspe
serumcsf
antibodi
ratio
exclus
alter
measl
viru
antibodi
p
leinikki
mcfarlin
shekarchi
j
sever
unpublish
observ
would
interest
studi
multipl
viru
antibodi
ratio
acut
inflammatori
diseas
mump
mening
uncompl
measl
enceph
neurosyphili
toxoplasmosi
